Everything below concerns pentadecapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-08. Numbers and descriptions here follow the published literature rather than marketing material.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
| Property | Value | Notes |
|---|---|---|
| Main study model | Rodents, rats and mice | Underpins most of the published data |
| Common routes in studies | Subcutaneous, intraperitoneal, oral | Varies with the experimental design |
| Common analytical method | Reversed-phase HPLC, LC-MS | Used for identity and purity checks |
| Human evidence base | Small | Few trials reported, with limited findings |
| Regulatory status | Varies by jurisdiction | Not an approved medicine in most places |
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
=== Discovery === In 1938, Emilio Segrè and Glenn T. Seaborg isolated for the first time the metastable isotope technetium-99m, after bombarding natural molybdenum with 8 MeV deuterons in the 37-inch (940 mm) cyclotron of Ernest Orlando Lawrence's Radiation laboratory. In 1970 Seaborg explained that:
Tin-121m (121mSn) is a nuclear isomer of tin with a half-life of 43.9 years, making it technically a medium-lived fission product. In a normal thermal reactor, it has a very low fission product yield; thus, this isotope is not a significant contributor to nuclear waste. Fast fission or fission of some heavier actinides will produce it at higher yields. For example, its yield from uranium-235 is 0.0007% per thermal fission and 0.002% per fast fission.
44 (Rhodesia) Squadron, based in Lincolnshire on the east coast, was a heavy bomber unit, and part of No. 5 Group in RAF Bomber Command's front line. Unlike the other two squadrons designated as "Rhodesian", No. 44 Squadron never had a Rhodesian majority, despite efforts to so populate it. Initially equipped with Hampdens, it became the first RAF squadron to convert to Lancasters at the end of 1941. It played a prominent part in the attack on the MAN diesel factory at Augsburg in April 1942. In March 1943 No. 44 Squadron took part in the Allied bombing of cities in northern Italy, including Genoa and Milan, as well as targets in Germany such as Wilhelmshaven, Cologne and Berlin.
=== Fortification === The World Health Organization does not have any recommendations for food fortification with vitamin E. The Food Fortification Initiative does not list any countries that have mandatory or voluntary programs for vitamin E. Infant formulas have alpha-tocopherol as an ingredient. In some countries, certain brands of ready-to-eat cereals, liquid nutrition products, and other foods have alpha-tocopherol as an added ingredient.
Ann Lawthom, lately Headteacher, Rhondda Special School, Trealaw, Rhondda. For services to Education. Hilda Blanche Le Cras. For services to Horse Driving for the Disabled and to the Royal British Legion on Guernsey. Elizabeth May Leake. For charitable services in Clenchwarton, Norfolk. William Gordon John Leckie, Managing Director, Cneff Hydro Hotel, Perthshire. For services to the Hotel Industry and to Tourism. Bryan Neville Lee. For services to the Samaritans and to the community in Doncaster. Winifred Elizabeth Lees. For political and public service. Jacqueline Margaret Leete. For services to the community in Headley, Hampshire. Donald Clement Lefever. For services to the Butler Trust. Shiu-Wing Leung, Executive Officer, Ministry of Defence. Joan Lewin. For services to the Historical Association. Ann Lewis, Teacher in Charge, Widden Family Centre, Gloucester. For services to Pre-School Education. Peter Reginald Lewis, Sub-Officer (Retained), North Wales Fire Service. For services to the Fire Service. Maurice George Lihou. For services to Young Handicapped People on Guernsey. Sandra Elizabeth Linnett, lately Sales and Computer Clerk, Kopex International Ltd. For services to Industry. Rose Helena Lloyd. For services to St. David's Church, Hundleton. Adrian Neville Barrett Loach, Assistant Group Scout Leader, Bristol. For services to Scouting. Rebecca McCausland Lockhead. For public service Jean Elizabeth Lockwood. For services to the community in Amersham, Buckinghamshire. The Reverend Roy Frederick Lodge, Chaplain, Her Majesty's Prison Brockhill.
Sources: en.wikipedia.org
=== Early observational studies === From the 1890s onwards, associations of tobacco use with cancers and vascular disease were regularly reported. In 1930, Fritz Lickint of Dresden, Germany, published a meta-analysis citing 167 other works to link tobacco use to lung cancer. Lickint showed that people with lung cancer were likely to be smokers. He also argued that smoking tobacco was the best way to explain the fact that lung cancer struck men four or five times more often than women (since women smoked much less), and discussed the causal effect of smoking on cancers of the liver and bladder.
== External links == https://www.inf.ethz.ch/personal/gonnet/DarwinManual/node148.html https://web.expasy.org/docs/relnotes/relstat.html The most recent statistics from the Swiss-Prot protein knowledgebase. Section 6.1 contains the most up-to-date amino acid frequencies Sources of PAM matrices:
=== Conflict with the US and its allies: 1981–1986 === The early 80s saw economic trouble in Libya; from 1982 to 1986, annual oil revenues dropped from $21 to $5.4 billion. Focusing on irrigation projects, 1983 saw construction start on Libya's largest and most expensive infrastructure project, the Great Man-Made River; although designed to be finished by the end of the decade, it remained incomplete at the start of the 21st century. Military spending increased, while other administrative budgets were cut. Foreign debt rose, and austerity measures were introduced to promote self-reliance; in 1985 there was a mass deportation of foreign workers, mostly Egyptian and Tunisian. Domestic threats continued to plague Gaddafi; in May 1984, his Bab al-Azizia home was unsuccessfully attacked by a militia—linked to the NFSL or Muslim Brotherhood—and in the aftermath 5,000 dissidents were arrested. In spring 1985, members of the military tried to assassinate Gaddafi twice. The first was a plot by conservative officers to assassinate him at a villa on the outskirts of Tripoli; the second was an assault on his convoy. In November 1985, Colonel Hassan Ishkal, the third most powerful man in Libya, head of the military region of Sirte, died in a suspicious car accident. Ishkal's death was attributed to Jalloud, Khalifa Hunaysh or Gaddafi.
The benefits of using heterologous expression here is that it produces large amounts of target receptors of drugs of interest, and is generally inexhaustible, reproducible, and inexpensive. These receptors could then be used in assays to test the effectiveness and specificity of drug binding. Moreover, the produced receptors themselves could be used as therapeutics. They could serve as decoys for toxins or excess signaling molecules, and bind/attenuate these molecules.
Sources: en.wikipedia.org
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.
They are best described as working hypotheses. Supporting data come mainly from cell cultures and animal tissue, using markers such as growth factors and inflammatory signals. Confirmatory human studies have not been reported.
Status depends on the country. In some places it is treated as a research chemical available without a prescription, while elsewhere it falls under prescription or controlled rules. It holds no general marketing approval as a therapeutic product.
Low temperature slows the chemical reactions, such as oxidation and hydrolysis, that break down a peptide chain. Water and oxygen are the main drivers of degradation, so a cold and dry environment extends usable life. Actual shelf life depends on the batch, the salt form, and the container.